Adcock Ingram expects substantial increase in interim earnings

Pharmaceuticals company Adcock Ingram expects its earnings per share (EPS) for the six-month period to December 31, 2016, to be at least 60% higher than the comparative period of 2015. The company noted that the 60c-a-share increase from the EPS of 99.6c reported in the prior year came on the back of certain nonrecurring capital profits, including the disposal of the group’s business in India.